Evidence map›Paper›PMID 41586499›Full record

ArticleAntimicrobial agents and chemotherapy2026

Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical

Julia Noack, Yesseinia Anglero-Rodriguez, Jonathan Gall, Jiayi Zhou, Sarah LeBlanc, Abigail Liebow, Anna Bakardjiev, Christy M Hebner, Lisa A Purcell, Vasant Jadhav and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Julia Noack *Vir Biotechnology, San Francisco, California, USA.
Yesseinia Anglero-Rodriguez *Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Jonathan GallVir Biotechnology, San Francisco, California, USA.
Jiayi ZhouVir Biotechnology, San Francisco, California, USA.
Sarah LeBlancAlnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Abigail LiebowAlnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Anna BakardjievVir Biotechnology, San Francisco, California, USA.
Christy M HebnerVir Biotechnology, San Francisco, California, USA.
Lisa A PurcellVir Biotechnology, San Francisco, California, USA.
Vasant JadhavAlnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Davide CortiVir Biotechnology, Bellinzona, Switzerland.ORCID 0000-0002-5797-1364
Florian A LemppVir Biotechnology, San Francisco, California, USA.ORCID 0000-0001-6103-8078

Funding

Alnylam Pharmaceuticals internal fundingVir Biotechnology internal funding
6 · The paper itself

Abstract

RNA interference (RNAi) therapeutics targeting hepatitis B virus (HBV) RNAs and monoclonal antibodies (mAbs) targeting HBV surface antigen (HBsAg) represent potential strategies for enabling functional cure in chronic HBV patients. Tobevibart (VIR-3434) is an investigational, Fc-engineered human mAb that targets HBsAg with pan-genotypic neutralizing activity. Elebsiran (VIR-2218) is an investigational small interfering RNA targeting a conserved region of the HBV genome. The

Indexed as

Antibodies, MonoclonalAntiviral AgentsHepatitis B Surface AntigensHepatitis B virusRNA, Small InterferingAnimalsDisease Models, AnimalDrug Therapy, CombinationHepatocytesHumansMiceMice, Inbred C57BLAntibodies, MonoclonalAntiviral AgentsHepatitis B Surface AntigensRNA, Small InterferingAAV-HBV miceantibodyelebsiranHBsAgHBVhuman-liver chimeric miceRNAi therapeuticsiRNAtobevibart

Identifiers

PMID41586499
PMCPMC12959159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.